TOPLINE:

Patients with diabetes using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may face more than twice the risk for developing neovascular age-related macular degeneration compared with those not using the medications, data from Canada showed. The risk appears to increase with longer exposure to the drugs.

METHODOLOGY:

Researchers conducted a population-based, retrospective cohort study using administrative data for 139,002 patients aged 66 years or older in Ontario, Canada, from January 2020 to November 2023.

The researchers matched 46,334 patients who had received a GLP-1 agent (predominantly semaglutide) for at least 6 months 1:2 with patients who had not received this type of medication, based on factors such as age, gender, duration of diabetes, and comorbidities.

T

See Full Page